Boehringer Ingelheim Seeks Dismissal of Antitrust Suit Over Inhaler Market Monopoly Allegations

Boehringer Ingelheim Pharmaceuticals Inc. and its entity Boehringer Ingelheim International GMBH have requested the dismissal of a proposed class action suit by health funds in a Connecticut federal court. The suit accuses the pharmaceutical company of monopolizing the inhaler market through improper patent listings. Boehringer argues that the lawsuit is baseless as it does not convincingly demonstrate that any competitors were actually impeded by the patents in question. Interested parties can explore further details of the case through Law360’s report on the matter.